Compare Infosys Limited (INFY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Viatris Inc — how do they compare? Infosys Limited trades at $12.25 (market cap $50.55B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Infosys Limited is far larger — about 2.7× Viatris Inc's market cap, and Infosys Limited pays the higher dividend (4.16%). Which is the better fit depends on your goals.
| INFY | VTRS | |
|---|---|---|
Market Cap | $50.55B | $18.69B |
Sector | Technology | Health |
52-Week High | $20.22 | $17.86 |
52-Week Low | $10.49 | $9.49 |
Enterprise Value | $48.30B | $30.80B |
Dividend Yield | 4.16% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.215, down 2.75% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators including RSI above 76. Fundamentally, the company maintains strong profitability with 16.37% net margins and 32.12% ROE, though Q2 2026 earnings missed expectations. Recent news highlights strategic AI collaborations with Metsä Group and Sentara Healthcare while Q1 2027 results showed revenue challenges but margin resilience.
The outlook remains cautious with analyst consensus at Hold (55%) and $11.05 price target below current levels. Key opportunities include growing AI revenue streams and strong cash flow generation, while risks involve revenue growth volatility and competitive IT services market pressures. The stock faces near-term headwinds from lowered growth guidance but maintains solid fundamentals.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
